非小细胞肺癌组织中粘蛋白抗原16的表达水平和突变的意义

Expression,Mutation and Clinical Significance of MUC16 in Non-small Cell Lung Cancer

【目的】探讨非小细胞肺癌(NSCLC)组织中粘蛋白抗原16(MUC16)的表达水平和突变情况。【方法】于本院就诊的113例NSCLC患者的癌组织为研究对象(A组);选取其癌旁正常组织作为对照组(B组)。采用实时荧光定量聚合酶链反应(qRT-PCR)检测NSCLS组织中MUC16 mRNA水平,同时在Ualcan数据库中检索MUC16在肺腺癌中的表达水平;采用免疫组织化学法检测组织MUC16蛋白表达水平;采用高通量测序技术鉴定NSCLC组织中MUC16基因的突变情况。分析MUC16 mRNA水平对NSCLC的诊断价值;分析NSCLC患者癌组织MUC16表达水平、突变情况与预后的关系。【结果】Ualcan数据库中,肺腺癌组织中MUC16 mRNA水平高于正常肺组织。A组MUC16 mRNA水平及蛋白阳性率高于B组(P<0.05)。MUC16 mRNA水平诊断NSCLC的曲线下面积(AUC)为0.882,截断值为1.213,特异性为84.1%,敏感度为83.2%。MUC16阳性NSCLC患者五年生存率为30.14%,低于MUC16阴性患者65.00%(P<0.05)。MUC16未突变NSCLC患者五年生存率为22.22%,低于MUC16突变患者的55.88%(P<0.05)。【结论】MUC16在NSCLC发生、发展过程中可能发挥重要作用,有一定的诊断价值,且其表达水平与突变情况与NSCLC预后密切相关,可能为NSCLC治疗提供新的潜在靶点。

【Objective】To detect the expression level and mutation of MUC16 in non-small cell lung cancer(NSCLC),and to explore the relationship of expression and mutation of MUC16 with prognosis.【Methods】A total of 113 patients with NSCLC in our hospital were selected as the research objects.The cancer tissues were in the observation group(A group)and the adjacent"normal"tissues were selected as the control group(B group).Real-time quantitative PCR(qRT-PCR)was used to detect the level of MUC16 mRNA in lung adenocarcinoma and the expression level of MUC16 in lung adenocarcinoma was retrieved from the Ualcan database.The immunohistochemistry was applied to detect the expression level of MUC16 protein.The high throughput sequencing was performed to identify the mutation of MUC16 gene in NSCLC.The diagnostic value of MUC16 mRNA in NSCLC was analyzed and the relationship of prognosis with MUC16 expression level and mutation in patients with NSCLC cancer was analyzed as well.【Results】In the Ualcan database,the level of MUC16 mRNA in lung adenocarcinoma tissue was shown higher than that in normal lung tissue(P<0.05).The level of MUC16 mRNA and protein positive rate in the A group were higher than those in the B group(P<0.05).The area under the curve(AUC)of MUC16 mRNA level in the diagnosis of NSCLC was 0.882,the cutoff value was 1.213,the specificity was 84.1%,and the sensitivity was 83.2%.The 5-year survival rate of MUC16 positive non-small cell lung cancer patients was 30.14%,which was lower than that of MUC16 negative patients(65.00%,P<0.05).The 5-year survival rate of 22.22%in patients with non MUC16 mutation was lower than that in patients with MUC16 mutation(55.88%,P<0.05).【Conclusion】MUC16 plays an important role in the occurrence and development of NSCLC cancer,and it has certain diagnostic value.Its expression level and mutation are closely related to the prognosis of NSCLC,which may provide a new potential target for the treatment of NSCLC.